Sorrento Therapeutics, Inc. (SRNE)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -539.92 Million USD | 4.94% |
| 2021 | -435.98 Million USD | -99.85% |
| 2020 | -275.69 Million USD | -4.79% |
| 2019 | -308.39 Million USD | -52.05% |
| 2018 | -147.09 Million USD | -302.67% |
| 2017 | 27.37 Million USD | 204.22% |
| 2016 | -60.33 Million USD | -941.33% |
| 2015 | -9.73 Million USD | 82.64% |
| 2014 | -31.54 Million USD | -54.88% |
| 2013 | -20.36 Million USD | -348.16% |
| 2012 | -4.55 Million USD | -47.97% |
| 2011 | -3.07 Million USD | -72.43% |
| 2010 | -1.78 Million USD | -92.01% |
| 2009 | -939.51 Thousand USD | -395.31% |
| 2008 | -187.28 Thousand USD | 30.79% |
| 2007 | -270.62 Thousand USD | 38.4% |
| 2006 | -439.28 Thousand USD | -42.61% |
| 2005 | -308.03 Thousand USD | -40271.04% |
| 2004 | -763.00 USD | 0.0% |
| 2003 | -763.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -85.3 Million USD | -13.63% |
| 2023 Q2 | -77.49 Million USD | 9.15% |
| 2022 Q4 | -75.06 Million USD | 29.65% |
| 2022 Q3 | -106.71 Million USD | -19.44% |
| 2022 FY | - USD | 4.94% |
| 2022 Q2 | -89.34 Million USD | 4.34% |
| 2022 Q1 | -93.39 Million USD | 7.67% |
| 2021 Q1 | 7.58 Million USD | 111.37% |
| 2021 Q2 | -162.1 Million USD | -2236.29% |
| 2021 Q3 | -85.15 Million USD | 47.47% |
| 2021 Q4 | -101.15 Million USD | -18.8% |
| 2021 FY | - USD | -99.85% |
| 2020 Q3 | -78.17 Million USD | -13.69% |
| 2020 FY | - USD | -4.79% |
| 2020 Q2 | -68.76 Million USD | -23.71% |
| 2020 Q1 | -55.58 Million USD | -7.54% |
| 2020 Q4 | -66.75 Million USD | 14.61% |
| 2019 Q2 | -46.02 Million USD | 51.47% |
| 2019 Q4 | -51.69 Million USD | 2.22% |
| 2019 FY | - USD | -52.05% |
| 2019 Q1 | -94.83 Million USD | -130.48% |
| 2019 Q3 | -52.86 Million USD | -14.87% |
| 2018 Q2 | -28.3 Million USD | 7.09% |
| 2018 Q4 | -41.14 Million USD | 4.77% |
| 2018 FY | - USD | -302.67% |
| 2018 Q1 | -30.46 Million USD | 59.5% |
| 2018 Q3 | -43.2 Million USD | -52.65% |
| 2017 Q3 | 94.99 Million USD | 850.89% |
| 2017 Q1 | -21.69 Million USD | -112.67% |
| 2017 FY | - USD | 204.22% |
| 2017 Q4 | -75.22 Million USD | -179.19% |
| 2017 Q2 | -12.65 Million USD | 41.69% |
| 2016 FY | - USD | -941.33% |
| 2016 Q2 | -44.12 Million USD | -151.57% |
| 2016 Q1 | -17.53 Million USD | 17.98% |
| 2016 Q3 | 14.53 Million USD | 132.95% |
| 2016 Q4 | -10.2 Million USD | -170.18% |
| 2015 Q2 | -9.92 Million USD | -6.15% |
| 2015 FY | - USD | 82.64% |
| 2015 Q3 | 35.19 Million USD | 454.42% |
| 2015 Q4 | -21.38 Million USD | -160.76% |
| 2015 Q1 | -9.35 Million USD | -29.36% |
| 2014 Q1 | -9.09 Million USD | 13.15% |
| 2014 FY | - USD | -54.88% |
| 2014 Q3 | -6.32 Million USD | 12.08% |
| 2014 Q2 | -7.19 Million USD | 20.92% |
| 2014 Q4 | -7.23 Million USD | -14.34% |
| 2013 Q3 | -2.99 Million USD | 33.24% |
| 2013 FY | - USD | -348.16% |
| 2013 Q1 | -2.4 Million USD | -44.39% |
| 2013 Q4 | -10.47 Million USD | -249.47% |
| 2013 Q2 | -4.48 Million USD | -86.31% |
| 2012 Q3 | -1.16 Million USD | -33.27% |
| 2012 FY | - USD | -47.97% |
| 2012 Q2 | -871.92 Thousand USD | -3.54% |
| 2012 Q1 | -842.15 Thousand USD | -19.33% |
| 2012 Q4 | -1.66 Million USD | -43.6% |
| 2011 Q1 | -669.38 Thousand USD | -269.95% |
| 2011 Q3 | -653.91 Thousand USD | 37.26% |
| 2011 FY | - USD | -72.43% |
| 2011 Q2 | -1.04 Million USD | -55.71% |
| 2011 Q4 | -705.72 Thousand USD | -7.92% |
| 2010 Q4 | -180.94 Thousand USD | 58.66% |
| 2010 Q1 | -594.22 Thousand USD | 12.87% |
| 2010 Q2 | -568.36 Thousand USD | 4.35% |
| 2010 Q3 | -437.66 Thousand USD | 23.0% |
| 2010 FY | - USD | -92.01% |
| 2009 Q3 | -225.19 Thousand USD | -183.88% |
| 2009 Q1 | -58.09 Thousand USD | -28.76% |
| 2009 FY | - USD | -395.31% |
| 2009 Q4 | -681.99 Thousand USD | -202.85% |
| 2009 Q2 | -79.32 Thousand USD | -36.55% |
| 2008 Q3 | -125.19 Thousand USD | -2203.86% |
| 2008 Q4 | -45.11 Thousand USD | 63.96% |
| 2008 Q2 | -5434.00 USD | 58.71% |
| 2008 Q1 | -13.16 Thousand USD | -77.41% |
| 2008 FY | - USD | 30.79% |
| 2007 Q3 | -10.64 Thousand USD | 15.69% |
| 2007 Q1 | -239.94 Thousand USD | 0.0% |
| 2007 FY | - USD | 38.4% |
| 2007 Q4 | -7418.00 USD | 30.28% |
| 2007 Q2 | -12.62 Thousand USD | 94.74% |
| 2006 FY | - USD | -42.61% |
| 2006 Q1 | - USD | 100.0% |
| 2005 Q3 | -191.00 USD | 0.0% |
| 2005 Q1 | -191.00 USD | -0.53% |
| 2005 FY | - USD | -40271.04% |
| 2005 Q4 | -307.45 Thousand USD | -160872.77% |
| 2005 Q2 | -191.00 USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | -191.00 USD | 0.0% |
| 2004 Q1 | -191.00 USD | 0.0% |
| 2004 Q3 | -191.00 USD | 0.0% |
| 2004 Q4 | -190.00 USD | 0.52% |
| 2003 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -120610.408% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -1729.892% |
| Biora Therapeutics, Inc. | -114.05 Million USD | -373.397% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -3325.722% |
| Better Therapeutics, Inc. | -38.26 Million USD | -1311.134% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -1311.023% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -2918.619% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -1500.593% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -1517.859% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -407.714% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -59007.166% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -1562.238% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -1056.361% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -9399.508% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -3212.198% |
| Molecular Templates, Inc. | 1.43 Million USD | 37857.203% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -3791.345% |
| NexImmune, Inc. | -28.16 Million USD | -1816.847% |
| Orgenesis Inc. | -60.71 Million USD | -789.239% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -952.614% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -735336.417% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -3244.187% |
| Scopus BioPharma Inc. | -11.71 Million USD | -4509.589% |
| Statera Biopharma, Inc. | 38.93 Million USD | 1486.744% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -7743.231% |
| Trevena, Inc. | -35.28 Million USD | -1430.061% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -963179.87% |
| Vaccinex, Inc. | -19.74 Million USD | -2634.09% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -51470.138% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -1052.166% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -7333.941% |